Engagement of Veterans With Lung Cancer (NCT07219251)

🧪 Interventions in This Study

• Lay Health Worker (LHW) Planning (BEHAVIORAL)
• Usual Care Group (OTHER)

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

1. Veteran patients with diagnosis of any stage of lung cancer;
2. 18 years of age or older;
3. English- or Spanish-speaking;
4. can self-administer questionnaires in English or Spanish;
5. valid telephone number;
6. receiving oncology care at participating sites;
7. currently newly diagnosed or receiving or having completed systemic anti-cancer therapy and/or radiation therapy within 12 months, defined as oral, injection, or intravenous therapy (chemotherapy, targeted therapy, or immunotherapy)

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (1 Sites)

• Veterans Affairs Palo Alto Health Care System (VAPAHCS) — Palo Alto, California

📞 Contact the Study Coordinator

Phone: (650) 493-5000

Email: manalip@stanford.edu

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Lung Cancer (NSCLC)

• GCC 2545- Improving Post-Radiotherapy Respiratory Function Through Sparing Serial and Parallel Components in the Lung — Baltimore, Maryland
• A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors — Orlando, Florida
• Study of Longitudinal Plasma PD-L1 Testing With Immunotherapy in Lung Cancer — Kingsport, Tennessee
• A Study of Orally Administered JBI-802 Alone or in Combination With Pembrolizumab for Patients With Non-small Cell Lung Cancer With an STK11 Mutation. — Cincinnati, Ohio
• GCC 2546- Motion Management — Baltimore, Maryland

Explore by condition: All Lung Cancer (NSCLC) clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.